Douglas R. Cary
Douglas R. Cary has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Ryo Mizojiri
Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
3 shared publications Hiroshi Banno
Axcelead Drug Discovery Partners, Inc., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
2 shared publications- Jun Fujimoto
Research, Takeda Pharmaceutical Co., Ltd., 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
2 shared publications - Masahiro Ito
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
2 shared publications Tomohiro Kawamoto
Research, Takeda Pharmaceutical Co., Ltd., 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
2 shared publications- Tomoya Sameshima
Research, Takeda Pharmaceutical Co., Ltd., 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
2 shared publications
Latest Publications
- 23 June 2026
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (7) , 1573-1580
Discovery of CTX-439: A Potent and Selective CDK12 Inhibitor as a Prospective Anti-Cancer Drug
Cyclin-dependent kinase 12 (CDK12) is a transcription-associated kinase critical in regulating transcription, mRNA splicing, translation, cell cycle progression, and DNA damage repair (DDR) pathways. CDK12 is a notable therapeutic target in cancer owing to its regulation of key DDR genes, including BRCA1 and BRCA2, which are essential in maintaining genomic stability. In this study, we describe the lead optimization of a 1,4-trans-cyclohexane-based series, resulting in the discovery of a novel and highly selective CDK12 inhibitor, CTX-439. CTX-439 demonstrated robust CDK12 inhibition, sustained potency against its homologous protein CDK13, and outstanding selectivity over other CDKs and the broader kinome. A comprehensive in vitro evaluation, including ADME-Tox profiling, identified CTX-439 as a promising drug candidate for targeted cancer therapy.
- 23 June 2026
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (7) , 1573-1580
Discovery of CTX-439: A Potent and Selective CDK12 Inhibitor as a Prospective Anti-Cancer Drug
Cyclin-dependent kinase 12 (CDK12) is a transcription-associated kinase critical in regulating transcription, mRNA splicing, translation, cell cycle progression, and DNA damage repair (DDR) pathways. CDK12 is a notable therapeutic target in cancer owing to its regulation of key DDR genes, including BRCA1 and BRCA2, which are essential in maintaining genomic stability. In this study, we describe the lead optimization of a 1,4-trans-cyclohexane-based series, resulting in the discovery of a novel and highly selective CDK12 inhibitor, CTX-439. CTX-439 demonstrated robust CDK12 inhibition, sustained potency against its homologous protein CDK13, and outstanding selectivity over other CDKs and the broader kinome. A comprehensive in vitro evaluation, including ADME-Tox profiling, identified CTX-439 as a promising drug candidate for targeted cancer therapy.
- 23 August 2021
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 25 (9) , 2029-2038
Extended Solution-phase Peptide Synthesis Strategy Using Isostearyl-Mixed Anhydride Coupling and a New C-Terminal Silyl Ester-Protecting Group for N-Methylated Cyclic Peptide Production
- 23 August 2021
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 25 (9) , 2029-2038
Extended Solution-phase Peptide Synthesis Strategy Using Isostearyl-Mixed Anhydride Coupling and a New C-Terminal Silyl Ester-Protecting Group for N-Methylated Cyclic Peptide Production
- 19 September 2019
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 10 (10) , 1498-1503
Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode
General control nonderepressible 2 (GCN2) is a master regulator kinase of amino acid homeostasis and important for cancer survival in the tumor microenvironment under amino acid depletion. We initiated studies aiming at the discovery of novel GCN2 inhibitors as first-in-class antitumor agents and conducted modification of the substructure of sulfonamide derivatives with expected type I half binding on GCN2. Our synthetic strategy mainly corresponding to the αC-helix allosteric pocket of GCN2 led to significant enhancement in potency and a good pharmacokinetic profile in mice. In addition, compound 6d, which showed slow dissociation in binding on GCN2, demonstrated antiproliferative activity in combination with the asparagine-depleting agent asparaginase in an acute lymphoblastic leukemia (ALL) cell line, and it also displayed suppression of GCN2 pathway activation with asparaginase treatment in the ALL cell line and mouse xenograft model.
- 19 September 2019
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 10 (10) , 1498-1503
Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode
General control nonderepressible 2 (GCN2) is a master regulator kinase of amino acid homeostasis and important for cancer survival in the tumor microenvironment under amino acid depletion. We initiated studies aiming at the discovery of novel GCN2 inhibitors as first-in-class antitumor agents and conducted modification of the substructure of sulfonamide derivatives with expected type I half binding on GCN2. Our synthetic strategy mainly corresponding to the αC-helix allosteric pocket of GCN2 led to significant enhancement in potency and a good pharmacokinetic profile in mice. In addition, compound 6d, which showed slow dissociation in binding on GCN2, demonstrated antiproliferative activity in combination with the asparagine-depleting agent asparaginase in an acute lymphoblastic leukemia (ALL) cell line, and it also displayed suppression of GCN2 pathway activation with asparaginase treatment in the ALL cell line and mouse xenograft model.
- Open Access
- 14 September 2017
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 8 (10) , 1077-1082
Discovery of Novel 5-(Piperazine-1-carbonyl)pyridin-2(1H)-one Derivatives as Orally eIF4A3-Selective Inhibitors
Starting from our previous eIF4A3-selective inhibitor 1a, a novel series of (piperazine-1-carbonyl)pyridin-2(1H)-one derivatives was designed, synthesized, and evaluated for identification of orally bioavailable probe molecules. Compounds 1o and 1q showed improved physicochemical and ADMET profiles, while maintaining potent and subtype-selective eIF4A3 inhibitory potency. In accord with their promising PK profiles and results from initial in vivo PD studies, compounds 1o and 1q showed antitumor efficacy with T/C values of 54% and 29%, respectively, without severe body weight loss. Thus, our novel series of compounds represents promising probe molecules for the in vivo pharmacological study of selective eIF4A3 inhibition.
- 14 September 2017
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 8 (10) , 1077-1082
Open AccessDiscovery of Novel 5-(Piperazine-1-carbonyl)pyridin-2(1H)-one Derivatives as Orally eIF4A3-Selective Inhibitors
Starting from our previous eIF4A3-selective inhibitor 1a, a novel series of (piperazine-1-carbonyl)pyridin-2(1H)-one derivatives was designed, synthesized, and evaluated for identification of orally bioavailable probe molecules. Compounds 1o and 1q showed improved physicochemical and ADMET profiles, while maintaining potent and subtype-selective eIF4A3 inhibitory potency. In accord with their promising PK profiles and results from initial in vivo PD studies, compounds 1o and 1q showed antitumor efficacy with T/C values of 54% and 29%, respectively, without severe body weight loss. Thus, our novel series of compounds represents promising probe molecules for the in vivo pharmacological study of selective eIF4A3 inhibition.
- 11 April 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (8) , 3335-3351
Discovery of Novel 1,4-Diacylpiperazines as Selective and Cell-Active eIF4A3 Inhibitors
Eukaryotic initiation factor 4A3 (eIF4A3), a member of the DEAD-box RNA helicase family, is one of the core components of the exon junction complex (EJC). The EJC is known to be involved in a variety of RNA metabolic processes typified by nonsense-mediated RNA decay (NMD). In order to identify molecular probes to investigate the functions and therapeutic relevance of eIF4A3, a search for selective eIF4A3 inhibitors was conducted. Through the chemical optimization of 1,4-diacylpiperazine derivatives identified via high-throughput screening (HTS), we discovered the first reported selective eIF4A3 inhibitor 53a exhibiting cellular NMD inhibitory activity. A surface plasmon resonance (SPR) biosensing assay ascertained the direct binding of 53a and its analog 52a to eIF4A3 and revealed that the binding occurs at a non-ATP binding site. Compounds 52a and 53a represent novel molecular probes for further study of eIF4A3, the EJC, and NMD.
- 11 April 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (8) , 3335-3351
Discovery of Novel 1,4-Diacylpiperazines as Selective and Cell-Active eIF4A3 Inhibitors
Eukaryotic initiation factor 4A3 (eIF4A3), a member of the DEAD-box RNA helicase family, is one of the core components of the exon junction complex (EJC). The EJC is known to be involved in a variety of RNA metabolic processes typified by nonsense-mediated RNA decay (NMD). In order to identify molecular probes to investigate the functions and therapeutic relevance of eIF4A3, a search for selective eIF4A3 inhibitors was conducted. Through the chemical optimization of 1,4-diacylpiperazine derivatives identified via high-throughput screening (HTS), we discovered the first reported selective eIF4A3 inhibitor 53a exhibiting cellular NMD inhibitory activity. A surface plasmon resonance (SPR) biosensing assay ascertained the direct binding of 53a and its analog 52a to eIF4A3 and revealed that the binding occurs at a non-ATP binding site. Compounds 52a and 53a represent novel molecular probes for further study of eIF4A3, the EJC, and NMD.